Appearing as a noteworthy breakthrough in the fight against obesity, the drug is attracting considerable attention . It combines the action of two known GLP-1 receptor agonists, dulaglutide , with an new glucose-dependent incretin component. Early clinical findings have indicated impressive fat reduction in people with excessive weight, perhaps of